Stock of the Day

September 30, 2021

Dr. Reddy's Laboratories (RDY)

$12.20
+$0.07 (+0.5%)
Market Cap: $10.18B

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Today's Trend

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is under pressure as investors digest a mixed but generally negative revision to the company’s longer-term earnings outlook. Shares have been trading below both their 50-day and 200-day moving averages and near the lower portion of their 12-month range, indicating subdued sentiment.

  • Zacks Research raised its Q3 2027 EPS estimate to $0.15 from $0.12 and its Q4 2027 estimate to $0.06 from $0.05. These increases provide a modest positive signal for near-term earnings expectations. MarketBeat Dr. Reddy’s Laboratories estimates
  • The latest estimates put full-year EPS at $0.45, while Zacks forecasts FY2027 EPS of $0.43, FY2028 EPS of $0.50 and FY2029 EPS of $0.61. The figures suggest earnings growth over time, but remain subject to revisions. MarketBeat Dr. Reddy’s Laboratories estimates
  • Zacks Research reduced numerous forecasts, including FY2027 EPS to $0.43 from $0.51, FY2028 EPS to $0.50 from $0.60 and FY2029 EPS to $0.61 from $0.66. It also cut estimates for several 2028 quarters and lowered Q1 2029 EPS to $0.14 from $0.18. The broad downward revisions likely outweigh the isolated increases to the Q3 and Q4 2027 forecasts. MarketBeat Dr. Reddy’s Laboratories estimates
  • The company’s most recent quarterly report showed EPS of $0.06, below the $0.09 consensus estimate, while revenue was approximately in line with expectations. The earnings miss may reinforce concerns reflected in the analysts’ estimate cuts. MarketBeat Dr. Reddy’s Laboratories quarterly results
← Previous Stock of the DayNext Stock of the Day →

Recent News